PUBLIC COMPANY
saveRISING
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- 8 companies hiring in New YorkLooking for a biopharma job in New York? Jobs on BioSpace have soared year over year and month over month.biospace · 5h ago
- Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 16h ago
- Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 16h ago
- Biogen set up for growth even without M&A but CEO won’t rule it outBiogen is growing as planned, with marketed products generating more revenue and multiple late-stage readouts expected over the next year. Building out an early-stage pipeline would be a bonus, CEO…biospace · 17h ago
- 2026 IPO stock tracker: How newly public biotechs are performingBioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.biospace · 21h ago
- STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technologyA STAT investigation found that Epic selectively withholds access to patient data, disadvantaging rival software developers and stymying innovation.stat · 1d ago
- Biotechs going to market alone must learn to go globalDrug developers increasingly have the option of seeking regulatory approval and commercializing a medicine themselves, rather than accepting an early exit offer. Doing so requires a worldwide strat…biospace · 1d ago
- Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are each hoping to raise around $134 million from their respective IPOs.fiercebiotech · 2d ago
- STAT+: Nonprofit Bon Secours Mercy Health strikes $5.7 billion deal for surgery center chainThe deal would make the Catholic system one of the largest operators of outpatient surgery centers.stat · 2d ago
- STAT+: HHS relaxes security, transparency rules for health record software used by hospitalsThe Trump administration removed several security, privacy and transparency requirements for vendors of EHR software.stat · 2d ago
comments(0)
5-min edit window · permanent after that